Send to

Choose Destination
Blood Adv. 2017 Dec 8;1(26):2572-2578. doi: 10.1182/bloodadvances.2017009852. eCollection 2017 Dec 12.

Aging, hematopoiesis, and the myelodysplastic syndromes.

Author information

Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY; and.
Department of Pathology, New York University School of Medicine, New York, NY.


The aging hematopoietic system undergoes numerous changes, including reduced production of red blood cells and lymphocytes as well as a relative increase in the production of myeloid cells. Emerging evidence indicates that many of these changes are due to selection pressures from cell-intrinsic and cell-extrinsic factors that result in clonal shifts in the hematopoietic stem cell (HSC) pool, resulting in predominant HSC clones that exhibit the functional characteristics associated with HSC aging. Given the recent descriptions of clonal hematopoiesis in aged populations, the increased risk of developing hematologic malignancies in individuals with clonal hematopoiesis, and the many similarities in hematopoietic aging and acquired bone marrow failure (BMF) syndromes, such as myelodysplastic syndromes (MDS), this raises significant questions regarding the relationship between aging hematopoiesis and MDS, including the factors that regulate HSC aging, whether clonal hematopoiesis is required for the development of MDS, and even whether BMF is an inevitable consequence of aging. In this article, we will review our current understanding of these processes and the potential intersections among them.

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests. Off-label drug use: None disclosed.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center